Edwards is issuing cautious commentary on consensus EPS estimates for 2025, according to contacts. While Edwards executives continue to present, shares are down $3.99, or 6%, to $64.94.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Enhances Shareholder Value Post-Divestiture
- Becton Dickinson completes purchase of Critical Care from Edwards Lifesciences
- Edwards Lifesciences call volume above normal and directionally bullish
- Edwards Lifesciences put volume heavy and directionally bearish
- Unusually active option classes on open August 29th